Graphs depicting absolute change (mean ± SEM) in LS, FN, and TH BMD during denosumab treatment and after receiving no subsequent therapy or received subsequent treatment with risedronate, alendronate, or zoledronic acid. From "Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study."

What’s New in Osteoporosis and Fragility Fractures 2023

/ Hip, Knee, Spine, Trauma, What's New

Vitamin D supplementation, fracture risk, and osteoporosis drug therapies are among several topics explored in recent studies featured in the …